Microsoft (NASDAQ:MSFT) and Novo Nordisk (NYSE:NVO)
In a multi-year partnership, Microsoft (NASDAQ:MSFT) and Novo Nordisk (NYSE:NVO) will combine the computational services, cloud computing, and artificial intelligence (AI) of the tech giant with the drug discovery, development, and data science skills of the Danish corporation.
According to a press release from Novo on September 12, under the terms of the partnership, Microsoft will supply AI technology, fundamental scientific models, and expertise while collaborating with Novos data scientists and subject matter experts from early research and development areas to accelerate the pharmaceutical companys R&D.
According to Lars Fogh Iversen, senior vice president, Digital Science & Innovation at Novo Nordisk, We are very happy about this new cooperation that allows us to engage closely with key specialists from Microsoft as we aim to develop our digital science and AI capabilities. Novo said that the collaborations AI models will be used in numerous use cases, the first two of which are already being carried out.
In order to gain scientific insights, one use case focuses on the automated summary and analysis of data from sources like literature, patents, scientific reports, and discussion forums. The second use case, meanwhile, tries to create models that forecast an individuals chance of developing atherosclerosis, a cardiovascular condition brought on by the accumulation of fat and cholesterol in the arterial walls. According to the business, the AI will also be used to build illness biomarkers and identify new targets.
The collaborations AI models will be used for a variety of use cases, the first two of which are now being carried out. In order to achieve new scientific insights, one use case focuses on the automated summary and analysis of data from sources like literature, patents, scientific reports, and discussion forums.
The development of models that forecast a persons risk of developing atherosclerosis, a cardiovascular disease brought on by the accumulation of lipids, cholesterol, and other chemicals in and on the walls of the arteries, is the goal of a second use case. The AI will also be used to build illness biomarkers and find new targets.
Microsoft stock Outlook
The drop in IT stock prices today may be exposing certain deals. Investors who were anticipating a fall on Tuesday were shocked by the increase in August inflation statistics, which led to a sell-off in IT companies.
Meanwhile, there is a bleak forecast for the PC industry, which is hurting stocks like Intel, Microsoft, and HP.
In other news, the adverse economic situation has prompted Microsoft, among the large tech companies, to effect sweeping job cuts.
Featured Image- Megapixl @Shiningcolors
Visit PressReach.com To Get More Articles Like This
Author: Jowi Kwasu
Market Jar Media Inc.
#170 – 422 Richards Street
Vancouver, BC, Canada